Ascendis Pharma A/S (NASDAQ:ASND) Q4 2024 Earnings Call Transcript February 12, 2025 Ascendis Pharma A/S beats earnings expectations. Reported EPS is $-0.68699, expectations were $-1.32. Operator ...

SKYTROFA has achieved a leading position in value in the U.S. growth hormone market. And for TransCon CNP, we have a clear path to submit our NDA and MAA as a differentiated treatment of ...

The potential upside from other products like Yorvipath and TransCon CNP is seen as a counterbalance to Skytrofa's current underperformance. Ascendis Pharma's pipeline includes TransCon CNP ...

TransCon hGH (lonapegsomatropin, marketed as Skytrofa) sales reached 58.5 million euros. Also Read: Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug TransCon PTH ...

SKYTROFA has achieved a leading position in value in the U.S. growth hormone market. And for TransCon CNP, we have a clear path to submit our NDA and MAA as a differentiated treatment of ...